Search
Shigella Sonnei Dysenteries
go.drugbank.com/conditions/DBCOND0083031Synonyms: (Shigella dysenteriae - group A) or (bacillary dysentery)Tetracycline
go.drugbank.com/drugs/DB00759ApprovedInvestigationalVet approvedWithdrawnTetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. … The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: (4S,4aS,5aS,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamideCardiolipin Biosynthesis CL(a-13:0/a-13:0/a-13:0/a-13:0)
smpdb.ca/view/SMP0043663DiseaseA mutated tafazzin gene disrupts this post-synthetic remodeling and causes Barth syndrome (BTHS), an X-linked human disease (PMID: 16973164). … Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/a-13:0/a-13:0/a-25:0)
smpdb.ca/view/SMP0043667DiseaseA mutated tafazzin gene disrupts this post-synthetic remodeling and causes Barth syndrome (BTHS), an X-linked human disease (PMID: 16973164). … Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/a-13:0/a-15:0/a-15:0)
smpdb.ca/view/SMP0043682DiseaseA mutated tafazzin gene disrupts this post-synthetic remodeling and causes Barth syndrome (BTHS), an X-linked human disease (PMID: 16973164). … Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/a-13:0/a-15:0/a-17:0)
smpdb.ca/view/SMP0043683DiseaseA mutated tafazzin gene disrupts this post-synthetic remodeling and causes Barth syndrome (BTHS), an X-linked human disease (PMID: 16973164). … Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/a-13:0/a-17:0/a-13:0)
smpdb.ca/view/SMP0043698DiseaseA mutated tafazzin gene disrupts this post-synthetic remodeling and causes Barth syndrome (BTHS), an X-linked human disease (PMID: 16973164). … Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/a-13:0/a-17:0/a-21:0)
smpdb.ca/view/SMP0043701DiseaseA mutated tafazzin gene disrupts this post-synthetic remodeling and causes Barth syndrome (BTHS), an X-linked human disease (PMID: 16973164). … Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/a-13:0/a-21:0/a-17:0)
smpdb.ca/view/SMP0043718DiseaseA mutated tafazzin gene disrupts this post-synthetic remodeling and causes Barth syndrome (BTHS), an X-linked human disease (PMID: 16973164). … Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/a-13:0/a-21:0/a-25:0)
smpdb.ca/view/SMP0043720DiseaseA mutated tafazzin gene disrupts this post-synthetic remodeling and causes Barth syndrome (BTHS), an X-linked human disease (PMID: 16973164). … Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.